Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
Geneoscopy has successfully closed a $105 million Series C funding round, led by Bio-Rad Laboratories (NYSE: BIO). The funding will support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.
The investment round included participation from notable investors including Petrichor, Labcorp, Morningside Ventures, and others. Geneoscopy's technology combines RNA isolation from stool samples with Bio-Rad's Droplet Digital™ PCR technology for effective cancer screening. Through a partnership with Labcorp, ColoSense will be made widely available to healthcare providers.
This funding follows FDA approval of ColoSense and aims to address the rising incidence of colorectal cancer, particularly among people under 50. The test offers a non-invasive alternative to traditional colonoscopies, potentially increasing screening accessibility for millions of eligible individuals who currently avoid testing.
Geneoscopy ha chiuso con successo un round di finanziamento di serie C da 105 milioni di dollari, guidato da Bio-Rad Laboratories (NYSE: BIO). Il finanziamento supporterà il lancio di ColoSense®, un test di screening non invasivo per il cancro colorettale, e favorirà l'innovazione diagnostica per le malattie infiammatorie intestinali.
Il round di investimento ha visto la partecipazione di investitori di spicco, tra cui Petrichor, Labcorp, Morningside Ventures e altri. La tecnologia di Geneoscopy combina l'isolamento dell'RNA dai campioni di feci con la tecnologia Droplet Digital™ PCR di Bio-Rad per un efficace screening del cancro. Attraverso una partnership con Labcorp, ColoSense sarà reso ampiamente disponibile ai fornitori di assistenza sanitaria.
Questo finanziamento arriva dopo l'approvazione della FDA per ColoSense e mira a contrastare l'aumento dell'incidenza del cancro colorettale, in particolare tra le persone di età inferiore ai 50 anni. Il test offre un'alternativa non invasiva alle colonscopie tradizionali, con il potenziale di aumentare l'accessibilità allo screening per milioni di individui idonei che attualmente evitano i test.
Geneoscopy ha cerrado con éxito una ronda de financiamiento Serie C de 105 millones de dólares, liderada por Bio-Rad Laboratories (NYSE: BIO). La financiación apoyará el lanzamiento de ColoSense®, una prueba de detección no invasiva para el cáncer colorrectal, y avanzará en innovaciones diagnósticas para enfermedades inflamatorias del intestino.
La ronda de inversión incluyó la participación de inversores notables como Petrichor, Labcorp, Morningside Ventures y otros. La tecnología de Geneoscopy combina la aislamiento de RNA de muestras de heces con la tecnología Droplet Digital™ PCR de Bio-Rad para un efectivo screening del cáncer. A través de una asociación con Labcorp, ColoSense estará disponible de forma amplia para proveedores de salud.
Este financiamiento sigue a la aprobación de la FDA para ColoSense y tiene como objetivo abordar el aumento de la incidencia del cáncer colorrectal, particularmente entre personas menores de 50 años. La prueba ofrece una alternativa no invasiva a la colonoscopia tradicional, potencialmente aumentando la accesibilidad a la detección para millones de individuos elegibles que actualmente evitan las pruebas.
Geneoscopy는 1억 5백만 달러 규모의 C 시리즈 투자 라운드를 성공적으로 마감했으며, Bio-Rad Laboratories(NYSE: BIO)가 이를 이끌었습니다. 이번 자금 지원은 ColoSense®라는 비침습적 대장암 선별 검사 출시를 지원하고, 염증성 장 질환 진단 혁신을 발전시키는 데 사용될 것입니다.
이번 투자 라운드에는 Petrichor, Labcorp, Morningside Ventures 등 저명한 투자자들이 참여했습니다. Geneoscopy의 기술은 대변 샘플에서 RNA를 분리하는 기술과 Bio-Rad의 Droplet Digital™ PCR 기술을 결합하여 효과적인 암 선별을 가능하게 합니다. Labcorp와의 파트너십을 통해 ColoSense는 의료 제공자에게 널리 제공될 예정입니다.
이 자금은 ColoSense에 대한 FDA 승인이 나온 뒤 진행되었으며, 특히 50세 이하의 사람들 사이에서 증가하는 대장암 발생률 문제를 해결하는 것을 목표로 하고 있습니다. 이 검사는 전통적인 대장내시경에 대한 비침습적인 대안을 제공하며, 현재 검사를 기피하는 수백만 명의 적격 개인들이 보다 쉽게 선별 검사를 받을 수 있도록 할 수 있습니다.
Geneoscopy a réussi à clôturer un tour de financement de 105 millions de dollars en Série C, dirigé par Bio-Rad Laboratories (NYSE: BIO). Ce financement soutiendra le lancement de ColoSense®, un test de dépistage non invasif du cancer colorectal, et fera avancer les innovations diagnostiques pour les maladies inflammatoires de l'intestin.
Ce tour de financement a vu la participation d'investisseurs notables, notamment Petrichor, Labcorp, Morningside Ventures et d'autres. La technologie de Geneoscopy combine l'isolement de l'ARN à partir d'échantillons de selles avec la technologie Droplet Digital™ PCR de Bio-Rad pour un dépistage efficace du cancer. Grâce à un partenariat avec Labcorp, ColoSense sera largement disponible pour les prestataires de soins de santé.
Ce financement survient après l'approbation de la FDA pour ColoSense et vise à répondre à l'augmentation de l'incidence du cancer colorectal, en particulier chez les personnes de moins de 50 ans. Le test offre une alternative non invasive aux coloscopies traditionnelles, augmentant potentiellement l'accessibilité au dépistage pour des millions de personnes éligibles qui évitent actuellement les tests.
Geneoscopy hat erfolgreich eine Finanzierungsrunde der Serie C über 105 Millionen US-Dollar abgeschlossen, die von Bio-Rad Laboratories (NYSE: BIO) geleitet wurde. Die Finanzierung wird den Start von ColoSense®, einem nicht-invasiven Screenings Test auf kolorektalen Krebs, unterstützen und diagnostische Innovationen für entzündliche Darmerkrankungen vorantreiben.
Die Investmentrunde wurde von namhaften Investoren wie Petrichor, Labcorp, Morningside Ventures und anderen begleitet. Die Technologie von Geneoscopy kombiniert die RNA-Isolation aus Stuhlproben mit der Droplet Digital™ PCR-Technologie von Bio-Rad für ein effektives Krebs-Screening. Durch eine Partnerschaft mit Labcorp wird ColoSense weitreichend für Gesundheitsdienstleister verfügbar gemacht.
Diese Finanzierung folgt auf die Zulassung von ColoSense durch die FDA und zielt darauf ab, dem steigenden Auftreten von kolorektalem Krebs, insbesondere bei Menschen unter 50 Jahren, entgegenzuwirken. Der Test bietet eine nicht-invasive Alternative zu herkömmlichen Koloskopien und könnte die Zugänglichkeit von Screenings für Millionen von berechtigten Personen erhöhen, die derzeit Tests vermeiden.
- Secured substantial $105M Series C funding
- Recently obtained FDA approval for ColoSense test
- Partnership with Labcorp for broad market distribution
- Strategic investment from Bio-Rad strengthens technological capabilities
- None.
Insights
Bio-Rad's
Leading this funding round alongside established players like Labcorp demonstrates Bio-Rad's commitment to expanding its clinical diagnostics portfolio. The partnership leverages Bio-Rad's QXDx ddPCR platform while providing access to Labcorp's extensive distribution network, creating a powerful commercialization pathway for ColoSense.
For Bio-Rad shareholders, this investment offers exposure to the fast-growing liquid biopsy market while maintaining the company's core focus on diagnostic platforms. The deal structure mitigates direct development risk while providing meaningful upside through platform adoption and equity appreciation.
The ColoSense test represents a significant advancement in colorectal cancer screening technology. The combination of Geneoscopy's RNA isolation methodology with Bio-Rad's highly precise ddPCR platform addresses key clinical needs: high sensitivity for early detection and non-invasive sampling. This could substantially improve screening compliance rates, particularly among the younger population where incidence rates are rising.
The test's ability to detect both colorectal cancer and advanced adenomas is particularly noteworthy, as early intervention in pre-cancerous lesions significantly improves patient outcomes. The platform's potential expansion into inflammatory bowel disease diagnostics further demonstrates its versatility and market potential.
The FDA approval milestone validates the technology's clinical utility and positions the platform for rapid market adoption, especially given the recent guidelines lowering the screening age to 45. This expands the addressable patient population by approximately 20 million individuals.
Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease
The capital raise positions the company to achieve key milestones, including the launch and commercialization of Geneoscopy’s at-home, stool-based colorectal cancer screening test, ColoSense. The funding also enables the company to continue investing in its innovative pipeline of diagnostic tests for inflammatory bowel disease, addressing a critical unmet medical need.
Geneoscopy’s novel platform for isolating human RNA from stool samples, combined with the high sensitivity and specificity of Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology, allows for highly effective screening and detection of colorectal cancer. Further, Geneoscopy and Labcorp will work together to provide broad availability of ColoSense, enabling healthcare providers to conveniently order the test as part of their comprehensive screening programs.
“This past year, we achieved many significant milestones, most notably FDA approval of ColoSense,” said Andrew Barnell, CEO and co-founder of Geneoscopy. “We are extremely pleased to secure this financing, which reflects investor confidence in the potential of our RNA technology to address unmet needs in colorectal cancer and inflammatory bowel disease. This continued support will enable us to deliver innovative solutions that prioritize patient well-being and shape the future of gastrointestinal health.”
Norman Schwartz, CEO of Bio-Rad Laboratories, stated, "As a leader in clinical diagnostics and digital biology, Bio-Rad’s mission is to advance science and save lives by improving healthcare outcomes. Geneoscopy’s ColoSense screening test is designed for use with Bio-Rad’s QXDx ddPCR platform and demonstrates remarkable sensitivity in detecting colorectal cancer and advanced adenomas. With this investment, we look forward to supporting Geneoscopy’s development and commercialization efforts while advancing our Droplet Digital PCR platform as a foundational technology for oncology applications across the clinical diagnostics and translational research markets.”
Colorectal cancer is the second deadliest cancer in the
Geneoscopy’s CEO, Andrew Barnell, will present a company update and expand on plans for this funding round at the 43rd Annual J.P. Morgan Healthcare Conference in
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in
Bio-Rad Forward Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products, Geneoscopy’s ColoSense screening test, and supporting Geneoscopy’s development and commercialization efforts while advancing our droplet digital PCR platform as a foundational technology for oncology applications across the clinical diagnostics and translational research markets. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan," "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108387874/en/
Geneoscopy Media Contact
Andrea Sampson
Sampson Public Relations Group
asampson@sampsonprgroup.com
Geneoscopy Investor Contact
Carrie Mendivil / Ji-Yon Yi
Gilmartin Group
investors@geneoscopy.com
Bio-Rad Media Contact
Anna Gralinska
Corporate Communications
510-741-6643
cc@bio-rad.com
Bio-Rad Investor Contact
Edward Chung
Investor Relations
510-741-6104
ir@bio-rad.com
Source: Geneoscopy, Inc.
FAQ
How much did Geneoscopy raise in its Series C funding round in 2025?
What will Geneoscopy use the Series C funding for?
Who are the major investors in Geneoscopy's 2025 Series C round?
What is the partnership between Geneoscopy and Labcorp for?
What technology does Geneoscopy's ColoSense test use?
